AdvisorNet Financial, Inc - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
AdvisorNet Financial, Inc ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$48,534
-0.2%
713
+19.6%
0.00%0.0%
Q2 2023$48,651
+149.3%
596
+126.6%
0.00%
+100.0%
Q1 2023$19,512
+88.3%
263
+110.4%
0.00%
+100.0%
Q4 2022$10,360
+48.0%
125
+380.8%
0.00%0.0%
Q3 2022$7,000
-22.2%
26
+4.0%
0.00%0.0%
Q2 2022$9,000
-98.3%
25
-98.0%
0.00%
-97.1%
Q1 2022$537,000
-16.2%
1,2400.0%0.03%
-12.8%
Q4 2021$641,000
+7.2%
1,240
+0.4%
0.04%
-7.1%
Q3 2021$598,000
+7.6%
1,235
+0.1%
0.04%
+13.5%
Q2 2021$556,000
+18.0%
1,2340.0%0.04%
+8.8%
Q1 2021$471,000
-19.8%
1,234
-33.2%
0.03%
-27.7%
Q4 2020$587,000
+524.5%
1,848
+385.0%
0.05%
+487.5%
Q3 2020$94,000
-38.2%
381
-33.7%
0.01%
-33.3%
Q2 2020$152,000
+42.1%
575
+1.8%
0.01%
+20.0%
Q1 2020$107,000
-9.3%
565
+4.8%
0.01%0.0%
Q4 2019$118,000
+12.4%
5390.0%0.01%0.0%
Q3 2019$105,000
-6.2%
539
+0.2%
0.01%
-16.7%
Q2 2019$112,000
+4.7%
5380.0%0.01%
-7.7%
Q1 2019$107,000
+37.2%
538
+0.2%
0.01%
+18.2%
Q4 2018$78,000
-29.1%
5370.0%0.01%
-21.4%
Q3 2018$110,000
+39.2%
537
+0.2%
0.01%
+27.3%
Q2 2018$79,000
+146.9%
536
+149.3%
0.01%
+175.0%
Q1 2018$32,000
+14.3%
2150.0%0.00%0.0%
Q4 2017$28,0002150.00%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2021
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders